Equity Investments:
by entrepreneurs
for entrepreneurs.

Behr Capital Partners represents the interests of two families with an entrepreneurial background. We are seeking to invest in highly innovative companies along the below parameters.

  • Target Areas

    Medtech; Diagnostics; Research-, Service and Production Companies along the pharma value chain; associated digitalization plays

  • Financing Events

    Late-stage VC funding, growth capital, small- and mid-cap PE investments

  • Positioning

    We will act as co-investors only, be it on a deal-by-deal basis or as a limited partner of established investors

  • Ticket size

    2–20 Mio. EUR over the investment lifecycle of a portfolio company

  • Geographic focus

    DACH, Nordics, Europe

Mark Bleckmann

Managing Director

Vaihinger Straße 50
70567 Stuttgart, Germany

P +49 711 7224919 0
E info@behr-capital.com

Mark Bleckmann heads the Family Office since its inauguration in 2018. He previously held the position of CFO at Haselmeier Group, a medtech company active in the development, manufacturing and sale of innovative drug delivery devices. At Haselmeier he successfully led a M&A transaction, resulting in a trade sale of the group in 2020. As far as the assessment of innovative growth companies and equity investments are concerned, he brings knowledge from both sides of the table to the family office: from 2008 to 2016 he worked as Head of Finance for Immatics Biotechnologies, a venture backed biotech company in the immuno-oncology space. Mr. Bleckmann started his career at IBM where he held various finance positions. He holds degrees in business (ESB Business School) and philosophy (London School of Economics).